10x Genomics (NASDAQ:TXG) Stock Price Expected to Rise, UBS Group Analyst Says

10x Genomics (NASDAQ:TXG) had its target price upped by investment analysts at UBS Group from $13.00 to $14.00 in a research note issued on Friday,Benzinga reports. The firm presently has a “neutral” rating on the stock. UBS Group’s price objective indicates a potential downside of 3.85% from the stock’s previous close.

A number of other equities analysts also recently issued reports on the company. Piper Sandler assumed coverage on 10x Genomics in a research report on Thursday, September 11th. They set a “neutral” rating and a $15.00 price objective for the company. Deutsche Bank Aktiengesellschaft set a $14.00 price objective on shares of 10x Genomics and gave the stock a “hold” rating in a research report on Friday, August 8th. Morgan Stanley reduced their price target on shares of 10x Genomics from $18.00 to $17.00 and set an “overweight” rating for the company in a research report on Tuesday, August 12th. Barclays increased their price objective on 10x Genomics from $15.00 to $17.00 and gave the stock an “overweight” rating in a research note on Friday. Finally, Canaccord Genuity Group set a $16.00 target price on shares of 10x Genomics in a report on Monday, August 11th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, seven have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $13.88.

10x Genomics Trading Up 12.0%

Shares of NASDAQ:TXG traded up $1.56 on Friday, reaching $14.56. 4,679,523 shares of the company’s stock were exchanged, compared to its average volume of 3,209,924. The company has a fifty day moving average of $12.78 and a 200-day moving average of $11.69. 10x Genomics has a twelve month low of $6.78 and a twelve month high of $17.25. The company has a market capitalization of $1.81 billion, a price-to-earnings ratio of -20.80 and a beta of 2.13.

10x Genomics (NASDAQ:TXG) last released its earnings results on Thursday, November 6th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.05. The firm had revenue of $149.00 million for the quarter, compared to analyst estimates of $142.50 million. 10x Genomics had a negative net margin of 13.13% and a negative return on equity of 12.88%. The business’s quarterly revenue was down 1.7% compared to the same quarter last year. During the same period last year, the firm earned ($0.30) EPS. 10x Genomics has set its Q4 2025 guidance at EPS. As a group, equities research analysts forecast that 10x Genomics will post -1.43 EPS for the current fiscal year.

Insider Activity at 10x Genomics

In other news, insider Benjamin J. Hindson sold 7,486 shares of 10x Genomics stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $13.79, for a total value of $103,231.94. Following the completion of the sale, the insider owned 440,888 shares of the company’s stock, valued at $6,079,845.52. The trade was a 1.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Adam Taich sold 22,315 shares of the firm’s stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $13.79, for a total transaction of $307,723.85. Following the completion of the transaction, the chief financial officer directly owned 309,273 shares in the company, valued at approximately $4,264,874.67. This represents a 6.73% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 39,149 shares of company stock worth $539,865 over the last 90 days. Company insiders own 9.39% of the company’s stock.

Institutional Investors Weigh In On 10x Genomics

A number of hedge funds have recently bought and sold shares of the business. GAMMA Investing LLC lifted its holdings in 10x Genomics by 81.8% during the 1st quarter. GAMMA Investing LLC now owns 3,586 shares of the company’s stock worth $31,000 after buying an additional 1,614 shares during the last quarter. Teacher Retirement System of Texas bought a new position in 10x Genomics in the 1st quarter worth about $123,000. Envestnet Asset Management Inc. boosted its position in 10x Genomics by 14.5% during the 1st quarter. Envestnet Asset Management Inc. now owns 95,701 shares of the company’s stock worth $835,000 after acquiring an additional 12,136 shares during the period. Xponance Inc. increased its stake in 10x Genomics by 17.4% during the 1st quarter. Xponance Inc. now owns 12,010 shares of the company’s stock valued at $105,000 after buying an additional 1,778 shares during the period. Finally, CWM LLC raised its holdings in 10x Genomics by 112.3% during the first quarter. CWM LLC now owns 48,906 shares of the company’s stock worth $427,000 after purchasing an additional 25,868 shares in the last quarter. Institutional investors and hedge funds own 84.68% of the company’s stock.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.